INTRODUCTION
The pricing of novel cancer medicines is complex and controversial, with access to oncology medicines varying substantially across countries. 1 There is a lack of understanding of how oncology prices are set and the true value being delivered, and perception that new oncology medicines offer minor improvements in survival yet are vastly more expensive than previous treatment options. 2, 3 Oncology drug pricing is currently based upon the delivery form (e.g. infusion vial) and size of patient, which can cause uncertainty of budget impact and cost effectiveness. The average body mass of a patient is highly variable and vial size may not equate well to patient size, resulting in significant wastage. Oncology drugs are also developed for multiple indications and for use at different stages of disease progression, with value varying according to disease, thus there is the potential for lack of transparency of cost-effectiveness. 4 
OBJECTIVES
The objective of this study is to research global pricing schemes to identify innovative methods of pricing novel oncology medicines to address uncertainties of budget impact and cost-effectiveness faced by healthcare systems and R&D-based pharma companies.
METHODS
Of several pricing schemes researched, the main countries where risk-sharing agreements are observed are Italy, Sweden, the UK and the Netherlands. The UK and Italy have specific access schemes in oncology and more risk-sharing experiences, 2 thus these pricing schemes were analysed in detail. Based on the results, two novel pricing models applicable to a range of countries were developed: intervention-specific disease-related group (DRG)-based pricing and an outcomes-based license fee.
RESULTS

The United Kingdom
In 2014, a new 5-year voluntary scheme was agreed between the UK Department of Health and the Association of the British Pharmaceutical Industry, covering 90% of speciality drugs commercialized in the UK.
5
Two types of schemes are specified:
All oncology technology appraisals identified were reported as simple discounts (Table 1) . Only one scheme is currently in operation involving an outcomes component Velcade (bortezomib) for multiple myeloma. 
Table 1: NICE technology appraisals and discount schemes for cancer agents
In 2014, the UK Ministry of Health set-up a process granting early access to Promising Innovative Medicines (PIM), prior to EMA approval and formal NICE review. Drugs are funded by the manufacturers, who can collect real world evidence (RWE) and have discussions with regulators to speed up subsequent formal reimbursement.
12
The advanced melanoma medicines nivolumab (Opdivo; BMS) and pembrolizumab (Keytruda; Merck) were approved in 2015 via the PIM early access scheme.
13,14
Italy
Italy makes an extensive use of access schemes. The content of the schemes is not usually made public, but generally they belong to three categories: 2 In the field of oncology, most agreements are Payment by Results schemes (Table 2) . 
CONCLUSIONS
Current methods of pricing for innovative medicines add to rather than lessen uncertainty about value, and are based on an outdated rationale. Novel pricing methods, such as a license or specific DRG by indication, provide examples of how value can be matched to specific disease state, and to the value being delivered by pricing according to month of PFS or OS, rather than by the weight of chemical being sold, or the size of the patient being treated. Operational challenges will be required to be overcome when adopting new pricing systems, but a change in pricing schemes is desirable to help deal with uncertainties of dosing, patient weight and vial size. According to those charged with ordering, storing and dispensing medicines in pharmacies, these novel pricing mechanisms would require a significant shift in healthcare administrative procedures, such as financial accounting methods for purchasing and stock control of medicines, plus the tracking of individual patients to the medicines being provided for them, for a specific medical condition. However, it is clear that these methods could deliver many benefits to Payers, and serve as a method to measure patient outcomes prospectively and deliver important RWE. Therefore these, and other innovative methods, should be piloted to determine how healthcare administrative procedures can be adapted to accommodate these innovative pricing methods.
SUMMARY
New pricing mechanisms including DRG-based pricing or licensing for specific cancers could bring greater certainty of budget impact and value for specific illnesses. These methods should be piloted by healthcare systems to ensure practical application brings benefits without high service burden.
